echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Invivoscribe has introduced a new diagnostic test for coronary pneumonia

    Invivoscribe has introduced a new diagnostic test for coronary pneumonia

    • Last Update: 2021-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Inc., a global leader in precision diagnostic development and commercialization, announced today that it will begin providing new coronary pneumonia testing through its CLIA/CAP-certified and New York State-licensed LabPMM Reference Laboratory in San Diego, California. Medical workers can make appointments for diagnostic tests on suspected patients with neo-coronary pneumonia. Subjects could also choose to participate in an ongoing study aimed at accelerating the identification of promising candidate antibodies and vaccines using Invivoscribe's proprietary next-generation sequencing analysis and bioinsyngraphic platform.

    new coronary pneumonia ® tested for LabPMMLabPMM is a world-leading reference laboratory that provides molecular and accompanying diagnostic testing to healthcare professionals and hospitals, as well as support for clinical trials. Our new coronary pneumonia detection is a qualitative real-time reverse transcription polymerase chain reaction (RT-PCR) test that detects RNA templates for new coronavirus. This test has been shown to be sensitive enough to determine whether a person is infected with the new coronavirus. Acceptable sample types include nasopharyngeal (NP) and pharynx (OP) swabs collected in the General Transport Substing (UTM). Invivoscribe offers a collection kit consisting of nasopharyngeal swabs via UTM for easy testing by medical workers facing a shortage of sampling equipment. In addition, new coronary pneumonia subjects have the option to participate in our blood-based antibody testing study, which uses data from international standard testing currently conducted in hundreds of clinical laboratories in the United States, Europe, Asia and other parts of the world.

    , Chief Scientific Officer and CEO of Invivoscribe and LabPMM, said, "Our team is excited to support the global fight against the new coronavirus. We recognize the urgent need to strengthen testing services to help mitigate the continuing disruption caused by the epidemic. With our 25 years of experience, we are pleased to provide high-quality, rapid inspection and support. We are focused on providing society with more patient testing that is urgently needed. In addition, our proprietary next-generation immunochemical sequencing analysis and bio-information software is now available and applied around the world, enabling us to quickly identify and track the immune response of subjects infected with the new coronavirus. Using these vast international data sets, we are able to quickly identify clusters of specific antibody determinations produced against viruses to optimize bedside diagnostics and determine the best table for vaccine production. "

    about Invivoscribe, Inc. and LabPMM, LLC.Invivoscribe is a private biotechnology company dedicated to improving life through precision diagnostics. Invivoscribe and its whox-owned LabPMM clinical laboratories are industry leaders in providing molecular products, services and bio-information solutions to more than 700 clinical laboratories in more than 160 countries. Invivoscribe has successful collaboration experience with global pharmaceutical companies interested in developing and commercializing accompanying diagnostic technologies and provides regulatory and laboratory services expertise. (
    Invivoscribe, Inc., Inc.
    .)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.